

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

31 May 2026

### Evaluation of the effectiveness of Noscatem herbal syrup on the clinical symptoms of outpatients with COVID-19

#### Protocol summary

##### Study aim

Determining the effectiveness of Noscatem syrup in the treatment of outpatients Covid 19 and also evaluating its effects on reducing mortality or hospitalization due to (SARS-CoV-2)

##### Design

This is a double-blind clinical study of phases 2-3. This study will be performed on 140 patients who are divided into two groups. Randomly, a group of outpatients with COVID-19 are given Noscatem syrup three times a day, two tablespoons at a time, and a group of placebo is given the placebo syrup for 10 days with common medications. The blocking method and randomization site "Randomaize.com" are used for randomization. Patients are followed up during this period in terms of clinical symptoms and severity of the disease and the need for hospitalization.

##### Settings and conduct

This study is performed in 16-hour clinics of Covid-19 in Mashhad. In this study, the physician, patient, and data analyst are unaware of the medication.

##### Participants/Inclusion and exclusion criteria

Outpatients with COVID-19; Confirmation of RT-PCR test for SARS-CoV-2; Blood oxygen saturation more than 90%; Age 18-60 years;

##### Intervention groups

Placebo group: receiving common treatments + placebo syrup three times a day, 2 tablespoons each time (placebo syrup prepared by Tamad Pharmaceutical Company), Intervention group: receiving common treatments + Noscatem syrup prepared by Tamad Pharmaceutical Company three times a day, 2 tablespoons each time equivalent to 20 mg

##### Main outcome variables

The rate of recovery time from the time of randomization of patients to the improvement of clinical symptoms including fever, cough and myalgia

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20180103038199N11**

Registration date: **2022-02-09, 1400/11/20**

Registration timing: **prospective**

Last update: **2022-02-09, 1400/11/20**

Update count: **0**

##### Registration date

2022-02-09, 1400/11/20

##### Registrant information

##### Name

Vahid Reza Askari

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 51 3800 2264

##### Email address

askariv941@mums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-02-20, 1400/12/01

##### Expected recruitment end date

2023-03-19, 1401/12/28

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Evaluation of the effectiveness of Noscatem herbal syrup on the clinical symptoms of outpatients with COVID-19

**Public title**

Noscatem and COVID-19

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Outpatients with COVID-19 Confirmed with RT-PCR SPO2 more than 90% Age between 18 to 60 years old

**Exclusion criteria:**

Pregnant women Breastfeeding women

**Age**

From **18 years** old to **70 years** old

**Gender**

Both

**Phase**

2-3

**Groups that have been masked**

- Participant
- Care provider
- Outcome assessor

**Sample size**

Target sample size: **70**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

The volume of each block will be 4. Then write a list of blocks and assign numbers to them, for example (AABB (1) - BBAA (2) - BABA (3) - BAAB (4)) which according to the sample size of 140 people, we have 35 blocks. Then, random numbers between one and 35 are selected according to the Randomaize.com randomization site, and finally, the treatment allocation list is determined based on random numbers.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Due to the use of a placebo similar to interventional therapy, the physician associated with the participants and participants will not be informed of the assigned treatment and also the analyst will be unaware of the treatment assigned to the two groups. Finally, after analyzing the data, the researcher who prepared the packages reveals codes A and B.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1**

**Ethics committee**

**Name of ethics committee**

Ethics committee of Mashhad University of Medical Sciences

**Street address**

Deputy of Research and Technology of the University, Qurashi Building, Next to Hoveyze Cinema, University Street

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

9138813944

**Approval date**

2021-09-07, 1400/06/16

**Ethics committee reference number**

IR.MUMS.MEDICAL.REC.1400.375

**Health conditions studied****1****Description of health condition studied**

COVID-19 disease

**ICD-10 code**

U07.1

**ICD-10 code description**

COVID-19

**Primary outcomes****1****Description**

Time to recover from illness based on questionnaire

**Timepoint**

before intervention and 3, 7 and 14 days after beginning the intervention

**Method of measurement**

questionnaire

**Secondary outcomes**

empty

**Intervention groups****1****Description**

Intervention group: receiving common treatments, including adult cold two tablets every eight hours, one tablespoon of diphenhydramine syrup every 8 hours, vitamin C 1000 mg effervescent + Noscatem syrup (10 mg/5ml) prepared by Tamad Pharmaceutical Company three times a day and each time two tablespoons that is equivalent to 20 mg noscapine hydrochloride

**Category**

Treatment - Drugs

## 2

### Description

Control group: receiving common treatments, including adult cold two tablets every eight hours, one tablespoon of diphenhydramine syrup every 8 hours, vitamin C 1000 mg effervescent + placebo syrup three times a day, 2 tablespoons each time (placebo syrup prepared by Tamad Pharmaceutical Company)

### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

16hours corona centers

##### Full name of responsible person

Dr Vahid Reza Askari

##### Street address

Mashhad university of medical science, Azadi square

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9177948564

##### Phone

+98 51 3800 2000

##### Email

askariv@mums.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Mashhad University of Medical Sciences

##### Full name of responsible person

Dr Majid Ghaïour Mobarhan

##### Street address

Deputy of Research and Technology of the University  
, Qurashi Building, Next to Hoveyzeh Cinema,  
University Street

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9138813944

##### Phone

+98 51 3841 2081

##### Email

ramresearch@mums.ac.ir

##### Grant name

##### Grant code / Reference number

##### Is the source of funding the same sponsor organization/entity?

No

##### Title of funding source

Temad Pharmaceutical Company

##### Proportion provided by this source

100

##### Public or private sector

Public

##### Domestic or foreign origin

Domestic

##### Category of foreign source of funding

*empty*

##### Country of origin

##### Type of organization providing the funding

Industry

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Mashhad University of Medical Sciences

##### Full name of responsible person

Vahid Reza Askari

##### Position

Assistant professor of clinical pharmacology

##### Latest degree

Ph.D.

##### Other areas of specialty/work

Medical Pharmacy

##### Street address

Faculty of medicine, Paradise of University, Vakil-  
Abad Blvd., Azadi Sq., Mashhad

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9177948564

##### Phone

+98 51 3800 2000

##### Fax

##### Email

askariv@mums.ac.ir

## Person responsible for scientific inquiries

#### Contact

##### Name of organization / entity

Mashhad University of Medical Sciences

##### Full name of responsible person

Vahid Reza Askari

##### Position

Assistant professor of clinical pharmacology

##### Latest degree

Ph.D.

##### Other areas of specialty/work

Medical Pharmacy

##### Street address

Faculty of medicine, Paradise of University, Vakil-  
Abad Blvd., Azadi Sq., Mashhad

##### City

Mashhad

##### Province

Razavi Khorasan  
**Postal code**  
9177948564  
**Phone**  
+98 51 3800 2000  
**Fax**  
**Email**  
askariv@mums.ac.ir

9177948564  
**Phone**  
+98 51 3800 2000  
**Fax**  
**Email**  
askariv@mums.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Mashhad University of Medical Sciences  
**Full name of responsible person**  
Vahid Reza Askari  
**Position**  
Assistant professor of clinical pharmacology  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Medical Pharmacy  
**Street address**  
Faculty of medicine, Paradise of University, Vakil-  
Abad Blvd., Azadi Sq., Mashhad  
**City**  
Mashhad  
**Province**  
Razavi Khorasan  
**Postal code**

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available